Semglee has been approved for over a year as ... a longer-acting version of insulin glargine that made $300 million in the first quarter. The FDA approval was awarded to Mylan, which is now ...

The interchangeable Semglee product, which will allow substitution of Semglee for the reference product, Lantus(R), at the pharmacy counter, will be introduced before the end of the year.